Demiana Faltaos

Demiana Faltaos, PharmD, Ph.D. joined Olema in November 2020 as Vice President of Clinical Pharmacology, after spending six years at Mirati Therapeutics as Head of Clinical Pharmacology. While there, she helped advance three innovative, targeted therapies including a receptor tyrosine kinase inhibitor, a KRASG12C direct inhibitor, and a histone deacetylase inhibitor in various types of cancer from Pre-IND to Phase 3. Dr. Faltaos has over 17 years of experience in Clinical Pharmacology and Pharmacometrics including positions of increasing responsibility at Amylin Pharmaceuticals; Center for Drug Evaluation Research, Office of Clinical Pharmacology at the U.S. Food and Drug Administration; Johnson & Johnson Pharmaceutical Research & Development in Belgium, and the French National Institute of Health and Medical Research (INSERM). Her extensive experience includes IND, NDA, and sNDA submissions for several new molecular entities and marketed products such as Invega, Invega Sustenna, Risperdal Consta, Byetta, Bydureon and Myalept.

Dr. Faltaos received her Ph.D. in Pharmacology from René Descartes University of Paris V, Faculty of Pharmacy, has two masters degrees in Pharmacokinetics and Drug Metabolism and Clinical Pharmacology from the University of Paris XI and Henri-Poincaré University of Nancy I, Faculty of Pharmacy, and a Pharmacy degree from the University of Alexandria, Faculty of Pharmacy.